What does this research mean for the field?

A newly designed hydrazide-hydrazone derivative, PR4, demonstrates high predicted binding affinity, dynamic stability, and favorable transport dynamics with the HSP90AA1 protein, indicating its potential as a targeted therapeutic candidate for gastric cancer. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To design and evaluate novel hydrazide–hydrazone derivatives targeting human gastric cancer cells using an integrated computational drug discovery pipeline.

September 3, 2026Beni-Suef University Journal of Basic and Applied SciencesOpen Access

Design of novel hydrazide–hydrazone derivatives targeting MGC803 gastric cancer cell line by integrating 3D-QSAR, ADMET, network pharmacology, docking, MD simulations and biological efficacy

View Full Paper

Ask AI

Bookmark

Authors

LNLhoucine NaanaaiSidi Mohamed Ben Abdellah University AAAbdellah El AissouqSidi Mohamed Ben Abdellah University YAYassine El AlloucheSidi Mohamed Ben Abdellah University

Discussion

Member takes

Implication

In silico modeling demonstrates stable binding of novel hydrazide–hydrazone derivatives to HSP90AA1 in gastric cancer, highlighting compound PR4 as a viable antiproliferative drug candidate.

Key Points

To design and evaluate novel hydrazide–hydrazone derivatives targeting human gastric cancer cells using an integrated computational drug discovery pipeline.
Constructed a 3D-QSAR model to design novel candidates (PR1–PR4), followed by ADMET pharmacokinetic screening and target prediction via PharmMapper.
Identified the hub gene HSP90AA1 through network pharmacology and performed molecular docking, 100 ns molecular dynamics simulations, MM-PBSA free energy calculations, and ligand transport analysis.
Molecular docking and 100 ns molecular dynamics simulations confirmed high binding affinity and stable contact networks of PR1–PR4 within the active site of HSP90AA1.
Compound PR4 displayed a favorable MM-PBSA binding free energy of -26.47 ± 2.89 kcal/mol toward HSP90AA1 and demonstrated superior theoretical transport dynamics across tunnels 1 and 2 compared to geldanamycin.

Cite This Study

Naanaai et al. (2026) studied this question.

synapsesocial.com/papers/6a99353a636c6408cfa7d3ff https://doi.org/10.1186/s43088-026-00816-0

View Full Paper

Ask AI

Bookmark

Implication

In silico modeling demonstrates stable binding of novel hydrazide–hydrazone derivatives to HSP90AA1 in gastric cancer, highlighting compound PR4 as a viable antiproliferative drug candidate.

Design of novel hydrazide–hydrazone derivatives targeting MGC803 gastric cancer cell line by integrating 3D-QSAR, ADMET, network pharmacology, docking, MD simulations and biological efficacy

Discussion

Member takes

Implication

Key Points

Cite This Study

Design of novel hydrazide–hydrazone derivatives targeting MGC803 gastric cancer cell line by integrating 3D-QSAR, ADMET, network pharmacology, docking, MD simulations and biological efficacy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider